{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:51:06Z","timestamp":1779126666919,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["PDT 468"],"award-info":[{"award-number":["PDT 468"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["PDT 468"],"award-info":[{"award-number":["PDT 468"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["PDT 468"],"award-info":[{"award-number":["PDT 468"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["PDT 468"],"award-info":[{"award-number":["PDT 468"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) tumors can be partitioned into four biologically distinct consensus molecular subtypes (CMS1-4) using gene expression. Evidence is accumulating that tumors in different subtypes are likely to respond differently to treatments. However, to date, there is no clinical diagnostic test for CMS subtyping. In this study, we used novel methodology in a multi-cohort training domain (n\u2009=\u20091,214) to develop the ColoType scores and classifier to predict CMS1-4 based on expression of 40 genes. In three validation cohorts (n\u2009=\u20091,744, in total) representing three distinct gene-expression measurement technologies, ColoType predicted gold-standard CMS subtypes with accuracies 0.90, 0.91, 0.88, respectively. To accommodate for potential intratumoral heterogeneity and tumors of mixed subtypes, ColoType was designed to report continuous scores measuring the prevalence of each of CMS1\u20134 in a tumor, in addition to specifying the most prevalent subtype. For analysis of clinical specimens, ColoType was also implemented with targeted RNA-sequencing (Illumina AmpliSeq). In a series of formalin-fixed, paraffin-embedded CRC samples (n\u2009=\u200949), ColoType by targeted RNA-sequencing agreed with subtypes predicted by two independent methods with accuracies 0.92, 0.82, respectively. With further validation, ColoType by targeted RNA-sequencing, may enable clinical application of CMS subtyping with widely-available and cost-effective technology.<\/jats:p>","DOI":"10.1038\/s41598-020-69083-y","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T10:02:52Z","timestamp":1595325772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing"],"prefix":"10.1038","volume":"10","author":[{"given":"Steven A.","family":"Buechler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa T.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda B.","family":"Hummon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonia C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesim","family":"G\u00f6kmen-Polar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil S.","family":"Badve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"69083_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/path.4212","volume":"231","author":"E Budinska","year":"2013","unstructured":"Budinska, E. et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63\u201376 (2013).","journal-title":"J. Pathol."},{"key":"69083_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1755-8794-5-66","volume":"5","author":"A Schlicker","year":"2012","unstructured":"Schlicker, A. et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genom. 5, 66 (2012).","journal-title":"BMC Med. Genom."},{"key":"69083_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.28387","volume":"134","author":"P Roepman","year":"2014","unstructured":"Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134, 552\u2013562 (2014).","journal-title":"Int. J. Cancer"},{"key":"69083_CR4","doi-asserted-by":"publisher","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","volume":"10","author":"L Marisa","year":"2013","unstructured":"Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).","journal-title":"PLoS Med."},{"key":"69083_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.3174","volume":"19","author":"EMF de Sousa","year":"2013","unstructured":"de Sousa, E. M. F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614\u2013618 (2013).","journal-title":"Nat. Med."},{"key":"69083_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nm.3175","volume":"19","author":"A Sadanandam","year":"2013","unstructured":"Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619\u2013625 (2013).","journal-title":"Nat. Med."},{"key":"69083_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"69083_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","volume":"2","author":"N Song","year":"2016","unstructured":"Song, N. et al. Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: Secondary analysis of NSABP C-07\/NRG oncology randomized clinical trial. JAMA Oncol. 2, 1162\u20131169 (2016).","journal-title":"JAMA Oncol."},{"key":"69083_CR9","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.18.02258","volume":"37","author":"H Lenz","year":"2019","unstructured":"Lenz, H. et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB\/SWOG 80405 (Alliance). J. Clin. Oncol. 37, 1876\u20131885 (2019).","journal-title":"J. Clin. Oncol."},{"key":"69083_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/bjc.2017.448","volume":"118","author":"SR Kim","year":"2018","unstructured":"Kim, S. R. et al. Tumour sidedness and intrinsic subtypes in patients with stage II\/III colon cancer: Analysis of NSABP C-07 (NRG Oncology). Br. J. Cancer 118, 629\u2013633 (2018).","journal-title":"Br. J. Cancer"},{"issue":"Suppl","key":"69083_CR11","doi-asserted-by":"publisher","first-page":"abstr 3510","DOI":"10.1200\/JCO.2017.35.15_suppl.3510","volume":"35","author":"PW Sebastian Stintzing","year":"2017","unstructured":"Sebastian Stintzing, P. W. et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. J. Clin. Oncol. 35(Suppl), abstr 3510 (2017).","journal-title":"J. Clin. Oncol."},{"key":"69083_CR12","doi-asserted-by":"crossref","unstructured":"Allen, W. L. et al. Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy. JCO Precsion Oncol. 1\u201315 (2018).","DOI":"10.1200\/PO.17.00241"},{"key":"69083_CR13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1093\/annonc\/mdy410","volume":"29","author":"JK Mooi","year":"2018","unstructured":"Mooi, J. K. et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Ann. Oncol. 29, 2240\u20132246 (2018).","journal-title":"Ann. Oncol."},{"key":"69083_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/1078-0432.CCR-17-1234","volume":"24","author":"A Sveen","year":"2018","unstructured":"Sveen, A. et al. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin. Cancer Res. 24, 794\u2013806 (2018).","journal-title":"Clin. Cancer Res."},{"key":"69083_CR15","doi-asserted-by":"publisher","first-page":"18698","DOI":"10.18632\/oncotarget.24617","volume":"9","author":"A Okita","year":"2018","unstructured":"Okita, A. et al. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget 9, 18698\u201318711 (2018).","journal-title":"Oncotarget"},{"key":"69083_CR16","doi-asserted-by":"publisher","first-page":"16618","DOI":"10.1038\/s41598-017-16747-x","volume":"7","author":"PW Eide","year":"2017","unstructured":"Eide, P. W., Bruun, J., Lothe, R. A. & Sveen, A. CMScaller: An R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci. Rep. 7, 16618\u201316628 (2017).","journal-title":"Sci. Rep."},{"key":"69083_CR17","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2017.35.15_suppl.3509","volume":"35","author":"L Marisa","year":"2017","unstructured":"Marisa, L. et al. Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort. J. Clin. Oncol. 35, 3509 (2017).","journal-title":"J. Clin. Oncol."},{"key":"69083_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/1078-0432.CCR-16-0680","volume":"23","author":"A Trinh","year":"2017","unstructured":"Trinh, A. et al. Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry. Clin. Cancer Res. 23, 387\u2013398 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69083_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/biostatistics\/kxp059","volume":"11","author":"MN McCall","year":"2010","unstructured":"McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242\u2013253 (2010).","journal-title":"Biostatistics"},{"key":"69083_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"69083_CR21","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage iii colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117\u20133125 (2009).","journal-title":"J. Clin. Oncol."},{"key":"69083_CR22","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","DOI":"10.1038\/nature11252"},{"key":"69083_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkz114","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 47, e47 (2019).","journal-title":"Nucleic Acids Res."},{"key":"69083_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"69083_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","volume":"20","author":"JM Conroy","year":"2018","unstructured":"Conroy, J. M. et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J. Mol. Diagn. JMD 20, 95\u2013109 (2018).","journal-title":"J. Mol. Diagn. JMD"},{"key":"69083_CR26","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).","journal-title":"Genome Biol."},{"key":"69083_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clbc.2018.07.011","volume":"19","author":"SA Buechler","year":"2018","unstructured":"Buechler, S. A., G\u00f6kmen Polar, Y. & Badve, S. S. EarlyR: A robust gene expression signature for predicting outcomes of estrogen receptor-positive breast cancer. Clin. Breast Cancer 19, 17\u201326 (2018).","journal-title":"Clin. Breast Cancer"},{"key":"69083_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1198\/016214502760047131","volume":"97","author":"C Fraley","year":"2002","unstructured":"Fraley, C. & Raftery, A. E. Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 97, 611\u2013631 (2002).","journal-title":"J. Am. Stat. Assoc."},{"key":"69083_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.32614\/RJ-2016-021","volume":"8","author":"L Scrucca","year":"2016","unstructured":"Scrucca, L., Fop, M., Murphy, T., Brendan, & Raftery, A. E. mclust 5: Clustering, classification and density estimation using gaussian finite mixture models. R J. 8, 289 (2016).","journal-title":"R J."},{"key":"69083_CR30","volume-title":"Mixture Model-Based Classification xiii-212","author":"PD McNicholas","year":"2017","unstructured":"McNicholas, P. D. Mixture Model-Based Classification xiii-212 (CRC Press Taylor & Francis Group, Boca Raton, 2017)."},{"key":"69083_CR31","doi-asserted-by":"crossref","unstructured":"Sachs, M. C. plotROC: A tool for plotting ROC curves. J .Stat. Softw. 79, 1\u201319 (2017).","DOI":"10.18637\/jss.v079.c02"},{"key":"69083_CR32","doi-asserted-by":"crossref","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J .Stat. Softw. 28, 1\u201326 (2008).","DOI":"10.18637\/jss.v028.i05"},{"key":"69083_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/0962280206070637","volume":"15","author":"CT Le","year":"2006","unstructured":"Le, C. T. A solution for the most basic optimization problem associated with an ROC curve. Stat. Methods Med. Res. 15, 571\u2013584 (2006).","journal-title":"Stat. Methods Med. Res."},{"key":"69083_CR34","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1038\/s41598-019-43492-0","volume":"9","author":"C Ragulan","year":"2019","unstructured":"Ragulan, C. et al. Analytical validation of multiplex biomarker assay to stratify colorectal cancer into molecular subtypes. Sci. Rep. 9, 7665\u20137712 (2019).","journal-title":"Sci. Rep."},{"key":"69083_CR35","doi-asserted-by":"crossref","unstructured":"Mittempergher, L. et al. MammaPrint and BluePrint molecular diagnostics using targeted RNA next-generation sequencing technology. J. Mol. Diagn. JMD 21, 808\u2013823 (2019).","DOI":"10.1016\/j.jmoldx.2019.04.007"},{"key":"69083_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-019-0111-0","volume":"5","author":"BV Sinn","year":"2019","unstructured":"Sinn, B. V. et al. SETER\/PR: A robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5, 1\u20138 (2019).","journal-title":"NPJ Breast Cancer"},{"key":"69083_CR37","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-0032","volume":"22","author":"PD Dunne","year":"2016","unstructured":"Dunne, P. D. et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin. Cancer Res. 22, 4095\u20134104 (2016).","journal-title":"Clin. Cancer Res."},{"key":"69083_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/path.5051","volume":"245","author":"M Alderdice","year":"2018","unstructured":"Alderdice, M. et al. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies. J. Pathol. 245, 19\u201328 (2018).","journal-title":"J. Pathol."},{"key":"69083_CR39","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41416-018-0230-7","volume":"119","author":"A Trinh","year":"2018","unstructured":"Trinh, A. et al. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS\/RAF mutations: A study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. Br. J. Cancer 119, 1244\u20131251 (2018).","journal-title":"Br. J. Cancer"},{"key":"69083_CR40","doi-asserted-by":"publisher","first-page":"djw303","DOI":"10.1093\/jnci\/djw303","volume":"109","author":"I Ubink","year":"2017","unstructured":"Ubink, I. et al. A novel diagnostic tool for selecting patients with mesenchymal-type colon cancer reveals intratumor subtype heterogeneity. J. Natl. Cancer Inst. 109, djw303 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"69083_CR41","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/annonc\/mdy337","volume":"29","author":"K Chang","year":"2018","unstructured":"Chang, K. et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann. Oncol. 29, 2061\u20132067 (2018).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69083-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:28:02Z","timestamp":1670336882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69083"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69083-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Notre Dame has filed a patent application for ColoType with SAB as inventor. SAB is a founder of Claris GenomiX, Inc which is has obtained\u00a0a license for this technology. Other authors reported no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12123"}}